Cardiovascular

Increased Use of Recommended Drugs Explains Improved Trends in Prognosis after Myocardial Infarction

Soko Setoguchi
Soko Setoguchi

Douglas Zipes
Douglas Zipes

SOKO SETOGUCHI, Brigham And Women’s Hospital, Boston
COMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis

REFERENCE: Abstract 1018-148, American College of Cardiology New Orleans
The increased adherence to recommendations and guidelines for drug therapy after myocardial infarction during the last ten years has led to hoped-for improvements in outcomes and prognosis among patients treated. This is the finding of a study presented to the ACC meeting in New Orleans by Soko Setoguchi who discussed her group’s findings with Peter Goodwin.

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: Reduced Mortality and Repeat MI with Enoxaparin for Patients with ST Elevation Myocardial Infarction
  • HARVEY WHITE, Auckland City Hospital, New Zealand REFERENCE: European Heart Journal Advanced On-Line Publication April 24th, 2007 Enoxaparin could be the new

  • PREAMI: Perindopril Improves Remodelling in Older Patients with Acute Myocardial Infarction
  • Audio Medica talked with Roberto Ferrari , Vice President of the ESC, about the PREAMI study on the use of

  • Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study
  • Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007,

    Post a comment

    Subscribe to Audio Medica Podcast